Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fifth of China Goods Substandard (China)

This article was originally published in PharmAsia News

Executive Summary

The Chinese government reports that almost 20 percent of goods Chinese quality inspectors checked in the first half of this year were below standard. The General Administration of Quality Supervision, Inspection and Quarantine found that 80.9 percent of 7,200 products inspected passed scrutiny and that overall quality was improving. However, 19.1 percent of the tested goods were found to be laced with toxins or too many additives, without safety protections or lacking required label information. The checks did not cover exports, according to the report. Chinese leaders have demanded stricter food and medicine standards after a series of trade disputes over the quality of exports. "When serious quality problems are found, they will be strictly punished according to the law so that product quality is protected from the source," the Administration report said. (Click here for more

You may also be interested in...



The Quality Lowdown: US FDA Finding New Crop Of Data Integrity Problems

Manufacturers warned to keep better electronic records and not falsify data in recent warning letters, ICH adds three residual solvent limits for pharmaceuticals, and the Polish authority hits firm for GMP noncompliance.

Decision By US COVID-19 Testing Czar To Step Down Critiqued By Key Health Panel Senator

Washington State Sen. Patty Murray said at a 4 June health panel hearing that having USPHS Admiral Brett Giroir step down as the nation’s COVID-19 “Testing Czar” is a bad move, but HHS disagrees.

Pink Sheet Podcast: Merck’s Frazier Speaks Out, US FDA’s Hahn On Decisions, Operation Warp Speed, Worries About User Fee Goal Delays

Pink Sheet reporters and editor discuss Merck CEO Ken Frazier’s thoughts on racial inequity, FDA Commissioner’s explanation of coronavirus decision-making and Operation Warp Speed changes, and consider fears about the potential for user fee goal delays.

UsernamePublicRestriction

Register

MT142209

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel